Clinical trial NCT04276597: Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.
Official title: A Phase II, Non-Randomized, Open-Label, Single-center, Physician Sponsored Study to Determine the Safety and Effectiveness of Lu-177 DOTATOC in Adult Subjects With Somatostatin Receptor Expressing Pulmonary, Pheochromocytoma, paragangliomUnknown Primary, and Thymus Neuroendocrine Tumors (PUTNET) or Any Other Non-.GEP-NET.
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: PHASE2
Conditions: Pulmonary Neuroendocrine Neoplasm
Pheochromocytoma
Paraganglioma
Thymus Carcinoid
Unknown Primary Tumors
Neuroendocrine Tumors
Neuroendocrine Skin Carcinoma
Neuroendocrine Breast Tumor
Neuroendocrine Carcinoma Metastatic
Neuroendocrine Neoplasm of Ovary
Keywords: Neuroendocrine tumors
Thymus neuroendocrine
Unknown Primary
Paraganglioma
Pheochromocytoma
Pulmonary
Any other non-.GEP-NET
NET
Lead sponsor: Excel Diagnostics and Nuclear Oncology Center
Sponsor class: OTHER
First posted: 2020-02-19
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Determine the safety and effectiveness of Lu-177 DOTATOC in adult subjects with somatostatin receptor-expressing Pulmonary, Pheochromocytoma, Paraganglioma, Unknown primary, and Thymus neuroendocrine tumors or any other non-.GEP-NET.

The treatment regimen will consist of 4 doses of 200 (±10%) mCi 177Lu-DOTATOC administered at 8+/- 1-week intervals.


Eligibility criteria: Inclusion criteria:

* Signed informed consent.
* Subjects of either sex, aged ≥18 years.
* ECOG status 0-2.
* Life-expectancy of at least 12 weeks.
* Histologically/cytologically confirmed diagnosis of SSTR (+) neuroendocrine tumors of the lung, Pheochromocytoma, Paraganglioma, thymus, and unknown primary, unresectable or metastatic.
* Measurable disease per RECIST 1.1, on CT/MRI scans, defined as at least 1 lesion with ≥ 1 cm in longest diameter (lymph nodes along short axis \>15 mm).
* Appropriate diagnostic imaging studies, at the discretion of the P.I. including but not limited to CT, MRI , 18F-FDG PET/CT, NAF PET/CT bone scan, ultrasound, etc. of the tumor region or suspected area within the 4 weeks of dosing day.
* Somatostatin receptor positive (SSTR+) disease, as evidenced by available FDA, commercially of IND approved SSTR imaging (SRI), within 4 weeks prior to the first cycle
* Recent blood test results (within 2weeks pre-dose) as follows:
* Sufficient bone marrow capacity as defined by WBC ≥2,500/µl and WBC≥2,000/mm3 for subsequent cycles; platelets ≥ 100,000 (100 \* 103/mm3) for the first treatment and ≥75,000 for the subsequent therapies, Hgb ≥8.9 g/dl for the first treatment and 8.0 g/dl for the subsequent therapies, ANC ≥1500/mm3 for the first treatment and ≥1000/ mm3; for the subsequent therapies.
* ALT, AST values ≤3 times ULN
* Bilirubin: ≤3 times ULN
* Serum creatinine ≤ 150 µmol/liter or 1.7 mg/dl
* Negative pregnancy test in women capable of child-bearing within 48 hours of IMP administration.
* Serum albumin \> 3.0g/L (\<3 g/L may be acceptable at the discretion of investigator, if PT, PTT, and INR are within normal range)
* All available FDA-approved therapies for which the subject is eligible have been exhausted (with the exception of PRRT), unless available therapies are refused by the subject (with the exception of somatostatin analogue, octreotide, and somatuline).

Exclusion Criteria:

* Known hypersensitivity to any of the excipients of Lu-177 DOTATOC.
* Therapeutic use of any somatostatin analogue, including Sandostatin® LAR (within 28 days) and Sandostatin® (within 1 day) prior to treatment.
* Subjects with unusual hematological parameters, including an increased MCV (\>105fL), and especially in those who had previous chemotherapy, the advice of a hematologist should be sought for adequate further work-up
* Any subject who is taking concomitant medications that decrease renal function (such as aminoglycoside antibiotics).
* Female subjects who are pregnant, lactating or women of childbearing potential not willing to practice effective contraceptive techniques during the study period and for 67 days (more than 10 half-lives of 177Lu after the last treatment, or male subjects who have female partners of childbearing potential not willing to practice abstinence or effective contraception, during the study period and for 67 days after the last treatment.
* Current somatic or psychiatric disease/condition that may interfere with the objectives and assessments of the study.
* Indication for surgical lesion removal with curative potential
* Planned (for the period of study participation): chemotherapy, immunotherapy, radiation therapy (unless regional for pain relief) chemo-embolization, bland embolization, radio-embolization, treatment with cyclosporine-A.
* Known brain metastases; unless these metastases have been treated and stabilized 6 months prior to enrolment
* Completion of: (1) cytotoxic chemotherapy for less than 6 weeks; (2) a biological agent for less than 5 half-lives; and (3) radiation therapy (except regional for pain relief) for less than 6 weeks prior to study enrolment,
* Uncontrolled congestive heart failure; subjects suspected of having this condition need to show ejection fraction of \> 35% as determined by MUGA scan.
* Glomerular Filtration Rate (GFR) \< 35 mL/min
* Subjects with prior peptide receptor radionuclide therapy (PPRT).

Primary outcomes:
measure: Assessment of the overall response rate
timeFrame: 12 monts
Secondary outcomes:
measure: Progression Free Survival (rPFS) in subjects receiving 4 cycles of therapy Monitoring of the changes in quality of life (QOL) through assessment of ECOG performance status and a QOL subject questionnaire.
timeFrame: 12 months
Other outcomes:
Locations:
city: Houston
country: United States
facility: Excel Diagnostics and Nuclear Oncology Center
state: Texas
Study officials:
affiliation: Excel Diagnostics and Nuclear Oncology Center
name: Ebrahim Delpassand, MD
role: PRINCIPAL_INVESTIGATOR
affiliation: Excel Diagnostics and Nuclear Oncology Center
name: Rodolfo Nunez, MD
role: STUDY_DIRECTOR
affiliation: Excel Diagnostics and Nuclear Oncology Center
name: Afshin Shafie, MD
role: STUDY_DIRECTOR
affiliation: Excel Diagnostics and Nuclear Oncology Center
name: Ayman Gaber, MD
role: STUDY_DIRECTOR
References: